Bohrane Slama

1.1k total citations
9 papers, 166 citations indexed

About

Bohrane Slama is a scholar working on Hematology, Genetics and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Bohrane Slama has authored 9 papers receiving a total of 166 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 5 papers in Genetics and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Bohrane Slama's work include Acute Myeloid Leukemia Research (6 papers), Pharmacological Effects and Toxicity Studies (2 papers) and Multiple Myeloma Research and Treatments (2 papers). Bohrane Slama is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Pharmacological Effects and Toxicity Studies (2 papers) and Multiple Myeloma Research and Treatments (2 papers). Bohrane Slama collaborates with scholars based in France, Belgium and Austria. Bohrane Slama's co-authors include Jiří Mayer, Eduard Gasal, Janet Franklin, Michel Delforge, Sejal Badre, Uwe Platzbecker, Jeroen S. Goede, Bhakti Mehta, Argiris Symeonidis and Esther Natalie Olíva and has published in prestigious journals such as British Journal of Haematology, Leukemia and Genes Chromosomes and Cancer.

In The Last Decade

Bohrane Slama

9 papers receiving 162 citations

Peers

Bohrane Slama

HEMAT

GENET

MB

PHEOH

OSM

Jason Esposito United States

Andrei Coliţă Romania

Mari Luz Amigo Spain

L. Aljassem France

Erika Morsia Italy

Heinz Tuechler Austria

M. F. McMullin United Kingdom

Carlo Bodenizza Italy

Evandro M. Fagundes Brazil

Teresa Ferró Spain

Jason Esposito United States

Bohrane Slama

303 ×2.0

HEMAT

278 ×2.7

GENET

24 ×0.6

MB

9 ×0.6

PHEOH

20 ×1.7

OSM

Citations per year, relative to Bohrane Slama Bohrane Slama (= 1×) peers Jason Esposito

Countries citing papers authored by Bohrane Slama

Since Specialization

Citations

This map shows the geographic impact of Bohrane Slama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bohrane Slama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bohrane Slama more than expected).

Fields of papers citing papers by Bohrane Slama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bohrane Slama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bohrane Slama. The network helps show where Bohrane Slama may publish in the future.

Co-authorship network of co-authors of Bohrane Slama

This figure shows the co-authorship network connecting the top 25 collaborators of Bohrane Slama. A scholar is included among the top collaborators of Bohrane Slama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bohrane Slama. Bohrane Slama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Garnier, Séverine, Nadine Carbuccia, Arnaud Guillé, et al.. (2019). Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes Chromosomes and Cancer. 59(1). 30–39. 14 indexed citations

2.

Platzbecker, Uwe, Argiris Symeonidis, Esther Natalie Olíva, et al.. (2017). A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia. 31(9). 1944–1950. 84 indexed citations

3.

Platzbecker, Uwe, Argiris Symeonidis, Esther N. Oliva, et al.. (2017). A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in Low or Intermediate-1 (INT-1) Risk Myelodysplastic Syndromes (MDS). Leukemia Research. 55. S29–S30. 1 indexed citations

4.

Legros, Laurence, Bohrane Slama, Norbert Vey, et al.. (2011). Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. Annals of Hematology. 91(1). 39–46. 8 indexed citations

5.

Sibon, David, Giovanna Cannas, Thomas Prébet, et al.. (2011). Lenalidomide in lower‐risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis‐stimulating agents. British Journal of Haematology. 156(5). 619–625. 29 indexed citations

6.

Park, Sophie, Rosa Sapena, Charikleia Kelaïdi, et al.. (2011). Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. Leukemia Research. 35(11). 1530–1533. 16 indexed citations

7.

Tamburini, Jérôme, C. Elie, Sophie Park, et al.. (2008). Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leukemia Research. 33(4). 547–550. 11 indexed citations

8.

Stefenelli, Thomas, Heinz Sochor, Bohrane Slama, et al.. (1991). Transient myocardial perfusion abnormalities during cold provocation test in patients with arterial hyperreactivity.. PubMed. 80(10). 622–6. 2 indexed citations

9.

Češková, Eva, et al.. (1978). DH Ergotoxin (Spofa) sublingual tablets in the treatment of cerebrovascular insufficiency in involution: clinical and experimental psychologic study.. PubMed. 20(4). 266–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact